This protocol addresses patients with Multiple endocrine neoplasia type 2A (MEN2A) who have concurrent hyperparathyroidism. The coexistence of these conditions shapes both surgical decision-making and the selection of medical therapy.
In patients with hyperparathyroidism in the setting of MEN2A, surgical management is guided by the extent of visible parathyroid gland enlargement. Only visibly enlarged parathyroid glands should be resected, reflecting the targeted approach recommended in this syndrome.
In certain clinical situations — such as when surgical options are exhausted or unavailable — a class of medical agents may be considered as part of the management strategy. The full protocol specifies the indications, clinical criteria, and agent class in detail.
DOI: 10.1089/thy.2014.0335
In patients with HPTH only visibly enlarged parathyroid glands should be resected.
If the patient remains hyperparathyroid despite one or more re-operations, or the patient is not a candidate for parathyroidectomy, medical therapy with calcimimetics should be considered.
View source ↗